XPENTION GENETICS INC (XPNG)
Last Price: 0.030 Change: 0.005 Percent: 21% Target: 0.18
Shares Outstanding: 57,725,833
Market Cap: $1,674,049
Why we are picking XPNG as our next big stock:
Xpention Genetics, Inc. is a biotechnology company that was formed to develop both immunological and molecular tests for cancer detection in humans and animals as well as therapeutic vaccines and other treatment methods. Xpention, Inc., a wholly owned subsidiary of Xpention Genetics, Inc., and The University of Texas MD Anderson Cancer Center signed a Patent and Technology License Agreement granting Xpention the exclusive rights to patented technology for the detection of cancer based on a tumor marker known as p65, which has been demonstrated to have elevated levels in the blood of human cancer conditions.
The Company has recently received promising Phase I preliminary results from the research agreement. This data will be submitted to a panel of scientists for further evaluation. Upon receipt of the final report from UTHSCSA as well as the findings from Phase I review, the Company will announce the results.